1. Home
  2. SUNS vs VTYX Comparison

SUNS vs VTYX Comparison

Compare SUNS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUNS
  • VTYX
  • Stock Information
  • Founded
  • SUNS 2023
  • VTYX 2018
  • Country
  • SUNS United States
  • VTYX United States
  • Employees
  • SUNS N/A
  • VTYX N/A
  • Industry
  • SUNS Real Estate Investment Trusts
  • VTYX Medicinal Chemicals and Botanical Products
  • Sector
  • SUNS Real Estate
  • VTYX Health Care
  • Exchange
  • SUNS Nasdaq
  • VTYX Nasdaq
  • Market Cap
  • SUNS 148.2M
  • VTYX 154.9M
  • IPO Year
  • SUNS N/A
  • VTYX 2021
  • Fundamental
  • Price
  • SUNS $10.63
  • VTYX $1.24
  • Analyst Decision
  • SUNS Strong Buy
  • VTYX Buy
  • Analyst Count
  • SUNS 3
  • VTYX 4
  • Target Price
  • SUNS $13.42
  • VTYX $11.33
  • AVG Volume (30 Days)
  • SUNS 110.8K
  • VTYX 982.1K
  • Earning Date
  • SUNS 05-07-2025
  • VTYX 05-08-2025
  • Dividend Yield
  • SUNS 8.79%
  • VTYX N/A
  • EPS Growth
  • SUNS N/A
  • VTYX N/A
  • EPS
  • SUNS 1.02
  • VTYX N/A
  • Revenue
  • SUNS $13,066,680.00
  • VTYX N/A
  • Revenue This Year
  • SUNS $113.67
  • VTYX N/A
  • Revenue Next Year
  • SUNS $35.05
  • VTYX N/A
  • P/E Ratio
  • SUNS $10.38
  • VTYX N/A
  • Revenue Growth
  • SUNS 1342.10
  • VTYX N/A
  • 52 Week Low
  • SUNS $7.80
  • VTYX $0.78
  • 52 Week High
  • SUNS $15.74
  • VTYX $5.66
  • Technical
  • Relative Strength Index (RSI)
  • SUNS N/A
  • VTYX 50.66
  • Support Level
  • SUNS N/A
  • VTYX $1.15
  • Resistance Level
  • SUNS N/A
  • VTYX $1.48
  • Average True Range (ATR)
  • SUNS 0.00
  • VTYX 0.11
  • MACD
  • SUNS 0.00
  • VTYX 0.01
  • Stochastic Oscillator
  • SUNS 0.00
  • VTYX 44.19

About SUNS Sunrise Realty Trust Inc. Common Stock

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: